GDF15 and Cachexia: Similarly, LBL-049 exhibited high specificity for human and cynomolgus monkey GDF15 without cross-reactivity with other TGF-β family members, effectively blocking GDF15/GFRAL signaling in vitro and showing dose-dependent prevention of weight loss in cachexia models, outperforming ponsegromab at lower doses [196].